Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.

Gough SC, Jain R, Woo VC.

Expert Rev Endocrinol Metab. 2016 Jan 2;11(1):7-19. Epub 2015 Nov 18.

2.

Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring.

Takeishi S, Mori A, Fushimi N, Hachiya H, Yumura T, Ito S, Shibuya T, Ohashi N, Kawai H.

J Diabetes Investig. 2016 May;7(3):374-80. doi: 10.1111/jdi.12409. Epub 2015 Sep 6.

3.

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.

Ikushima I, Kaku K, Hirao K, Bardtrum L, Haahr H.

J Diabetes Investig. 2016 Mar;7(2):270-5. doi: 10.1111/jdi.12399. Epub 2015 Aug 27.

4.

Concentrated insulins: the new basal insulins.

Lamos EM, Younk LM, Davis SN.

Ther Clin Risk Manag. 2016 Mar 9;12:389-400. doi: 10.2147/TCRM.S99855. eCollection 2016. Review.

5.

Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice.

Kobuke K, Yoneda M, Nakanishi S, Ohno H, Maeda S, Egusa G.

J Diabetes Investig. 2016 Jan;7(1):94-9. doi: 10.1111/jdi.12373. Epub 2015 Jun 10.

6.
7.

Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.

Atkin S, Javed Z, Fulcher G.

Ther Adv Chronic Dis. 2015 Nov;6(6):375-88. doi: 10.1177/2040622315608646. Review.

8.

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes.

Thuillier P, Alavi Z, Kerlan V.

Diabetes Metab Syndr Obes. 2015 Oct 1;8:483-93. doi: 10.2147/DMSO.S54953. eCollection 2015. Review.

9.

Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study.

Tosaka Y, Kanazawa A, Ikeda F, Iida M, Sato J, Matsumoto K, Uchida T, Tamura Y, Ogihara T, Mita T, Shimizu T, Goto H, Ohmura C, Fujitani Y, Watada H.

Int J Endocrinol. 2015;2015:176261. doi: 10.1155/2015/176261. Epub 2015 Sep 7.

10.

Effects of High-Intensity Interval Exercise versus Moderate Continuous Exercise on Glucose Homeostasis and Hormone Response in Patients with Type 1 Diabetes Mellitus Using Novel Ultra-Long-Acting Insulin.

Moser O, Tschakert G, Mueller A, Groeschl W, Pieber TR, Obermayer-Pietsch B, Koehler G, Hofmann P.

PLoS One. 2015 Aug 28;10(8):e0136489. doi: 10.1371/journal.pone.0136489. eCollection 2015.

11.

Cardiovascular effects of basal insulins.

Mannucci E, Giannini S, Dicembrini I.

Drug Healthc Patient Saf. 2015 Jul 10;7:113-20. doi: 10.2147/DHPS.S43300. eCollection 2015. Review.

12.

Degludec: the new ultra-long insulin analogue.

Tambascia MA, Eliaschewitz FG.

Diabetol Metab Syndr. 2015 Jun 26;7:57. doi: 10.1186/s13098-015-0037-0. eCollection 2015.

13.

Update on strategies limiting iatrogenic hypoglycemia.

Bonaventura A, Montecucco F, Dallegri F.

Endocr Connect. 2015 Sep;4(3):R37-45. doi: 10.1530/EC-15-0044. Epub 2015 Jun 22. Review.

14.

Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.

Nakamura T, Sakaguchi K, So A, Nakajima S, Takabe M, Komada H, Okuno Y, Hirota Y, Nakamura T, Iida K, Kajikawa M, Nagata M, Ogawa W, Seino S.

Diabetologia. 2015 Sep;58(9):2013-9. doi: 10.1007/s00125-015-3648-y. Epub 2015 Jun 5.

15.

Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).

Morales J, Merker L.

Adv Ther. 2015 May;32(5):391-403. doi: 10.1007/s12325-015-0208-2. Epub 2015 May 12.

16.

Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions.

Kalra S, Gupta Y.

N Am J Med Sci. 2015 Mar;7(3):81-5. doi: 10.4103/1947-2714.153918. Review.

17.

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.

Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, Silverstein J, Tumini S, Ocampo Francisco AM, Kinduryte O, Danne T.

Pediatr Diabetes. 2015 May;16(3):164-76. doi: 10.1111/pedi.12263. Epub 2015 Feb 12.

18.

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.

Havelund S, Ribel U, Hubálek F, Hoeg-Jensen T, Wahlund PO, Jonassen I.

Pharm Res. 2015 Jul;32(7):2250-8. doi: 10.1007/s11095-014-1614-x. Epub 2015 Jan 8.

19.

Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.

Komuro M, Inoue G, Tabata M, Yamada Y, Atsuda K, Matsubara H, Irie J, Uchida J, Nakajima C, Izumi H, Shimada M, Yamada S.

J Diabetes Sci Technol. 2015 May;9(3):632-8. doi: 10.1177/1932296814564396. Epub 2014 Dec 18.

20.

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.

Becker RH, Nowotny I, Teichert L, Bergmann K, Kapitza C.

Diabetes Obes Metab. 2015 Mar;17(3):261-7. doi: 10.1111/dom.12416. Epub 2015 Jan 7.

Items per page

Supplemental Content

Write to the Help Desk